There was a moment during the MannKind (NASDAQ:MNKD) earnings call when we actually felt sorry for the company. A moment that quickly passed as this company has not earned any sympathy. To gauge just how bad things have become the call lasted less than 40 minutes and only 5 analysts even bothered to ask a question. The fact is reality is beginning to set in and analysts are now openly wondering whether the company can survive without Sanofi (NYSE:SNY).